Edgewise Therapeutics, Inc. (NASDAQ:EWTX) saw an uptick in trading volume on Thursday . 8,340 shares were traded during trading, a decline of 96% from the previous session’s volume of 187,528 shares.The stock last traded at $26.32 and had previously closed at $26.45.
A number of equities research analysts have recently issued reports on EWTX shares. The Goldman Sachs Group initiated coverage on shares of Edgewise Therapeutics in a research note on Monday, April 26th. They issued a “neutral” rating and a $31.00 price objective for the company. Wedbush started coverage on shares of Edgewise Therapeutics in a research report on Monday, April 26th. They set an “outperform” rating and a $38.00 price target for the company. SVB Leerink initiated coverage on Edgewise Therapeutics in a research note on Monday, April 26th. They set an “outperform” rating and a $34.00 price objective on the stock. Finally, JPMorgan Chase & Co. initiated coverage on Edgewise Therapeutics in a research note on Monday, April 26th. They issued an “overweight” rating and a $34.00 target price for the company.
The business has a fifty day simple moving average of $28.72.
Several institutional investors and hedge funds have recently made changes to their positions in the company. New Leaf Venture Partners L.L.C. bought a new position in Edgewise Therapeutics in the first quarter worth about $50,494,000. Federated Hermes Inc. purchased a new position in shares of Edgewise Therapeutics in the 1st quarter valued at approximately $20,044,000. Credit Suisse AG bought a new stake in shares of Edgewise Therapeutics during the first quarter valued at approximately $2,732,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Edgewise Therapeutics in the first quarter worth $290,000.
Edgewise Therapeutics Company Profile (NASDAQ:EWTX)
Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
See Also: Lock-Up Period Expiration
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.